- Home
- MNOV vs JSPR Comparison
MNOV vs JSPR Comparison
Compare MNOV & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNOV | JSPR |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.7M | 48.1M |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | MNOV | JSPR |
|---|---|---|
| Price | $1.28 | $1.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | $7.00 | ★ $21.44 |
| AVG Volume (30 Days) | 79.4K | ★ 4.0M |
| Earning Date | 02-18-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $257,917.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.13 | $1.39 |
| 52 Week High | $2.20 | $22.99 |
Technical Indicators
Market Signals| Indicator | MNOV | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 35.08 | 46.23 |
| Support Level | $1.23 | $1.61 |
| Resistance Level | $1.51 | $1.96 |
| Average True Range (ATR) | 0.05 | 0.12 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 16.18 | 40.85 |
Price Performance
Historical ComparisonAbout MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.